ARTICLE | Finance
Medicxi's platform exception
Why Medicxi made Gadeta an exception to the VC's asset-centric model
April 4, 2016 7:00 AM UTC
Medicxi Ventures spurned its typical asset-centric model for the second time this month because the firm thought Gadeta B.V.'s T cell receptor platform was too good an opportunity to pass up.
On March 29, Gadeta raised €7 million ($7.8 million) in a series A round led by Medicxi and Baxalta Ventures. Gadeta's founders, management and Utrecht Holdings also participated. ...